Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Acquired by Millennium Management LLC

Millennium Management LLC grew its position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 252.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,329,149 shares of the company's stock after buying an additional 951,779 shares during the period. Millennium Management LLC owned 1.14% of Applied Therapeutics worth $1,138,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Marshall Wace LLP boosted its position in shares of Applied Therapeutics by 144.8% during the 4th quarter. Marshall Wace LLP now owns 1,307,381 shares of the company's stock worth $1,124,000 after purchasing an additional 773,377 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Applied Therapeutics by 2,511.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company's stock worth $4,642,000 after purchasing an additional 5,213,370 shares during the period. Private Advisor Group LLC purchased a new position in shares of Applied Therapeutics during the 4th quarter worth approximately $35,000. Propel Bio Management LLC boosted its position in shares of Applied Therapeutics by 46.4% during the 4th quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company's stock worth $8,233,000 after purchasing an additional 3,047,562 shares during the period. Finally, Alyeska Investment Group L.P. boosted its position in shares of Applied Therapeutics by 175.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,707,497 shares of the company's stock worth $2,318,000 after purchasing an additional 1,725,824 shares during the period. Hedge funds and other institutional investors own 98.31% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on APLT shares. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $1.50 price objective on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen raised shares of Applied Therapeutics to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Applied Therapeutics presently has an average rating of "Hold" and an average target price of $6.10.

Applied Therapeutics Stock Up 1.5%

Applied Therapeutics stock traded up $0.01 during mid-day trading on Friday, reaching $0.37. 1,185,663 shares of the company's stock were exchanged, compared to its average volume of 3,386,708. The company has a market cap of $52.27 million, a P/E ratio of -0.23 and a beta of 1.86. Applied Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $10.62. The company has a fifty day moving average of $0.39 and a 200-day moving average of $0.98.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.61 million. Equities research analysts expect that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.